Paper36765765
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.
Finkelman BS and 3 others. Cancers (Basel), 2023. Cited by 49 papers, by iCite.
Cite this record
ConductScience Library. The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations. Papers, record 36765765. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36765765
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References184
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21297447 | Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. | Appl Immunohistochem Mol Morphol | 2011 | https://conductscience.org/library/papers/21297447 | PubMed |
| 2 | 35384873 | A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone. | Appl Immunohistochem Mol Morphol | 2022 | https://conductscience.org/library/papers/35384873 | PubMed |
| 3 | 28721378 | Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. | NPJ Breast Cancer | 2016 | https://conductscience.org/library/papers/28721378 | PubMed |
| 4 | 35955851 | Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35955851 | PubMed |
| 5 | 15591335 | A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15591335 | PubMed |
| 6 | 3020096 | Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. | J Clin Pathol | 1986 | https://conductscience.org/library/papers/3020096 | PubMed |
| 7 | 32300181 | Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. | Mod Pathol | 2020 | https://conductscience.org/library/papers/32300181 | PubMed |
| 8 | 30523750 | Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30523750 | PubMed |
| 9 | 10837136 | The Ki-67 protein: fascinating forms and an unknown function. | Exp Cell Res | 2000 | https://conductscience.org/library/papers/10837136 | PubMed |
| 10 | 24498305 | Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. | PLoS One | 2014 | https://conductscience.org/library/papers/24498305 | PubMed |
| 11 | 23958221 | WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. | Trials | 2013 | https://conductscience.org/library/papers/23958221 | PubMed |
| 12 | 16899776 | Concordance among gene-expression-based predictors for breast cancer. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16899776 | PubMed |
| 13 | 28045625 | Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28045625 | PubMed |
| 14 | 21372600 | Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. | Oncology | 2010 | https://conductscience.org/library/papers/21372600 | PubMed |
| 15 | 23584595 | Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. | Breast Cancer | 2015 | https://conductscience.org/library/papers/23584595 | PubMed |
| 16 | 25778295 | Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. | J BUON | 2015 | https://conductscience.org/library/papers/25778295 | PubMed |
| 17 | 32879492 | Chromosome clustering by Ki-67 excludes cytoplasm during nuclear assembly. | Nature | 2020 | https://conductscience.org/library/papers/32879492 | PubMed |
| 18 | 6706431 | The long-term prognostic significance of the thymidine labelling index in breast cancer. | Int J Cancer | 1984 | https://conductscience.org/library/papers/6706431 | PubMed |
| 19 | 30395177 | Breast Cancers With Magee Equation Score of Less Than 18, or 18-25 and Mitosis Score of 1, Do Not Require Oncotype DX Testing: A Value Study. | Am J Clin Pathol | 2019 | https://conductscience.org/library/papers/30395177 | PubMed |
| 20 | 18230798 | Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. | J Natl Cancer Inst | 2008 | https://conductscience.org/library/papers/18230798 | PubMed |
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42923317 | Immunohistochemical Expression of Proliferating Cell Nuclear Antigen in Invasive Breast Carcinoma: Associations With Histological Grade and Ki-67 Expression. | Cureus | 2026 | https://conductscience.org/library/papers/42923317 | PubMed |
| 42861134 | Moran's index habitat and peritumoral radiomics based on digital breast tomosynthesis for predicting Ki-67 status in breast cancer. | Quant Imaging Med Surg | 2026 | https://conductscience.org/library/papers/42861134 | PubMed |
| 42618942 | Predicting ki-67 expression in breast cancer via transformer and multiple instance learning on DCE-MRI. | Cancer Imaging | 2026 | https://conductscience.org/library/papers/42618942 | PubMed |
| 42487966 | Study on the predictive efficacy of Ki-67, ER, and PR levels on the effectiveness of neoadjuvant chemotherapy in breast cancer. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42487966 | PubMed |
| 42316062 | Distinguishing Ki67 stratification expression in ER-positive/HER2-negative breast cancers: comparison of advanced MRI diffusion models. | BMC Med Imaging | 2026 | https://conductscience.org/library/papers/42316062 | PubMed |
| 42192906 | Artificial Intelligence in Oncology: A Comprehensive Cross-Cancer Translational Readiness Analysis Across 18 Malignancies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42192906 | PubMed |
| 42174497 | Noninvasive prediction of Ki67 proliferation index in breast cancer based on integrated photoacoustic imaging. | BMC Med Imaging | 2026 | https://conductscience.org/library/papers/42174497 | PubMed |
| 42088208 | Predicting dynamic changes of Ki-67 in breast cancer after neoadjuvant therapy based on multi-phase DCE-MRI delta-radiomics. | Front Oncol | 2026 | https://conductscience.org/library/papers/42088208 | PubMed |
| 41948524 | Prognostic Value of Ki-67 and Progesterone Receptor for Risk Stratification and Outcomes by Adjuvant Chemotherapy in Early Luminal-Type Breast Cancer. | Breast Cancer (Dove Med Press) | 2026 | https://conductscience.org/library/papers/41948524 | PubMed |
| 41728598 | A pathology-based surrogate model for chemotherapy decision-making in intermediate-risk luminal breast cancer: validation of histologic grade and Ki67 in a Chinese population. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/41728598 | PubMed |
| 41215873 | Predictors and nomogram for upstaging to invasive breast carcinoma in ductal carcinoma in situ diagnosed by ultrasound-guided core needle biopsy. | Gland Surg | 2025 | https://conductscience.org/library/papers/41215873 | PubMed |
| 41149862 | Omission of Sentinel Lymph Node Biopsy in Early-Stage HER2+ and Triple-Negative Breast Cancer: A Retrospective Analysis. | J Pers Med | 2025 | https://conductscience.org/library/papers/41149862 | PubMed |
| 41114097 | Contrast-enhanced ultrasound as a non-invasive diagnostic modality for pancreatic ductal adenocarcinoma: The question of Ki67 for study validation. | World J Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/41114097 | PubMed |
| 40951896 | Predictive value of serum glutathione S-transferase (GST-â), P-glycoprotein (PGP), P53, KI-67 in breast cancer: A systematic review and meta-analysis. | J Med Biochem | 2025 | https://conductscience.org/library/papers/40951896 | PubMed |
| 40734715 | Androgen Receptor and Tumor-Associated Neutrophil Expression Across Breast Cancer Subtypes: Associations With Clinicopathological Characteristics. | Int J Breast Cancer | 2025 | https://conductscience.org/library/papers/40734715 | PubMed |
| 40448815 | Ki-67 and 21-gene recurrence score assay in decision making for adjuvant chemotherapy in breast cancer patients. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40448815 | PubMed |
| 40361968 | Advanced Deep Learning Approaches in Detection Technologies for Comprehensive Breast Cancer Assessment Based on WSIs: A Systematic Literature Review. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/40361968 | PubMed |
| 40235755 | The value of morphological magnetic resonance imaging features combined with diffusion kurtosis imaging for predicting Ki-67 expression levels in high-grade gliomas. | Quant Imaging Med Surg | 2025 | https://conductscience.org/library/papers/40235755 | PubMed |
| 40201702 | Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review. | Health Sci Rep | 2025 | https://conductscience.org/library/papers/40201702 | PubMed |
| 39964132 | Imaging-Based Prediction of Ki-67 Expression in Hepatocellular Carcinoma: A Retrospective Study. | Cancer Med | 2025 | https://conductscience.org/library/papers/39964132 | PubMed |
Genes15
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36765765
GET https://conductscience.org/api/papers/v1/36765765/references?page=2